STOCK TITAN

Meiragtx Holdings Plc - MGTX STOCK NEWS

Welcome to our dedicated page for Meiragtx Holdings Plc news (Ticker: MGTX), a resource for investors and traders seeking the latest updates and insights on Meiragtx Holdings Plc stock.

MeiraGTx Holdings Plc (NASDAQ: MGTX) is a clinical-stage leader in gene therapy innovation, developing transformative treatments for ocular, neurological, and salivary gland disorders. This dedicated news hub provides investors and industry professionals with timely updates on the company’s progress, regulatory milestones, and strategic initiatives.

Access authoritative information directly from corporate announcements and verified sources. Track developments across MeiraGTx’s pipeline including clinical trial results for inherited retinal diseases, Parkinson’s disease research updates, and advancements in radiation-induced xerostomia therapies. The repository also features financial disclosures, manufacturing expansions, and partnership announcements.

Key updates include progress on the company’s proprietary riboswitch platform, AAV vector manufacturing innovations, and regulatory interactions. All content is curated to support informed analysis of MeiraGTx’s position in the gene therapy landscape while maintaining strict compliance with financial reporting standards.

Bookmark this page for streamlined access to essential MGTX updates. Combine our news tracking with Stock Titan’s analysis tools to monitor the company’s progress in advancing genetic medicines from clinical development to potential commercialization.

Rhea-AI Summary

MeiraGTx reported positive data from the Phase 1 AQUAx study, received a $50 million milestone for the Phase 3 LUMEOS clinical trial, and remains on track with clinical development for various programs. The company highlighted significant progress in gene therapy programs for xerostomia and Parkinson's disease. The riboswitch platform shows promising results in metabolic disease models. Financially, the company had cash and cash equivalents of $120.3 million as of March 31, 2024, and anticipates having sufficient capital until the first quarter of 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.78%
Tags
-
Rhea-AI Summary
MeiraGTx Holdings plc (NASDAQ: MGTX) announced its participation in upcoming investor conferences. Alexandria Forbes, Ph.D., President, and CEO will present at Chardan 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit, BofA Securities Healthcare Conference 2024, and Goldman Sachs 45th Annual Global Healthcare Conference. Live webcasts will be available on the Investors page of the Company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.09%
Tags
conferences
-
Rhea-AI Summary
MeiraGTx gave an oral presentation at the American Academy of Oral Medicine Annual Conference on a Phase 1 study of gene therapy for radiation-induced xerostomia. The study showed significant improvements in patient-reported outcomes and saliva flow rates, indicating the treatment's effectiveness and safety.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.6%
Tags
none
Rhea-AI Summary
MeiraGTx Holdings plc (MGTX) announces financial results and operational updates, including progress in clinical programs for radiation-induced xerostomia, retinal diseases, and Parkinson's disease. The company aligns with FDA for Phase 2 AQUAx2 trial, presents positive data at AAOM, and enters agreements with Janssen and Sanofi. MeiraGTx also reports successful treatment outcomes for LCA4 patients and advancements in riboswitch gene regulation technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.09%
Tags
-
Rhea-AI Summary
MeiraGTx receives $50 million milestone for Phase 3 LUMEOS trial extension study for XLRP treatment. Anticipates further milestone payments and revenue from commercial sales and manufacturing agreement with J&J.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.55%
Tags
none
-
Rhea-AI Summary
Sanofi makes a strategic equity investment in Graviton Bioscience, granting a 12-month right of first negotiation to explore collaboration opportunities across various indications, including immunological and metabolic syndrome indications. Graviton Bioscience is focused on therapies that inhibit Rho/Rho-associated coiled-coil containing protein kinase 2 (ROCK2) and other therapeutic compounds. The investment aims to drive the momentum behind ROCK2 inhibitor treatments, which are implicated in the pathology of metabolic, autoimmune, inflammatory, and neurologic disorders with inadequate or no treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.66%
Tags
none
Rhea-AI Summary
MeiraGTx Holdings plc (Nasdaq: MGTX) enters into an Asset Purchase Agreement with Janssen Pharmaceuticals, Inc. for the treatment of X-linked retinitis pigmentosa (XLRP) related to botaretigene sparoparvovec (bota-vec), securing up to $415 million. The agreement includes $130 million in upfront and near-term milestone payments, with potential additional revenue from commercial sales and manufacturing technology transfer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
32.59%
Tags
none
-
Rhea-AI Summary
MeiraGTx Holdings plc (MGTX) announced the participation of its President and CEO, Dr. Alexandria Forbes, in two upcoming investor conferences. The live webcasts of the corporate presentations will be available on the Investors page of the company’s website, with replays accessible for approximately 30 days following the presentation dates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.28%
Tags
conferences
-
Rhea-AI Summary
MeiraGTx Holdings plc (Nasdaq: MGTX) announced a strategic investment from Sanofi, purchasing $30 million of ordinary shares at $7.50 per share. They also announced a right of first negotiation (ROFN) with Sanofi for the use of MeiraGTx’s Riboswitch gene regulation technology for certain CNS and I&I targets, including IL-4 and IL-13, as well as for GLP-1 and other gut peptides for metabolic disease. Enrollment in the Phase 2 study of AAV2-hAQP1 for the treatment of RIX is ongoing. The company presented eight posters at the ESGCT 2023 Annual Congress and received a 2nd Commercial Manufacturer’s/Importer’s Authorization (MIA) for QC testing at their manufacturing facility in Shannon, Ireland.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.33%
Tags
Rhea-AI Summary
MeiraGTx Holdings plc announced that Sanofi has made a $30 million strategic investment in the company. Sanofi will purchase 4.0 million ordinary shares at a price of $7.50 per share. Sanofi will also receive a right of first negotiation for the use of MeiraGTx's Riboswitch gene regulation technology for certain Immunology and Inflammation and Central Nervous System targets, as well as for metabolic disease. MeiraGTx is actively pursuing strategic options with other interested parties.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.27%
Tags
none
Meiragtx Holdings Plc

Nasdaq:MGTX

MGTX Rankings

MGTX Stock Data

426.61M
46.68M
39.24%
58.91%
2.53%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
NEW YORK